Can you provide a reference chart of inhaler medications for COPD and asthma, including maintenance and rescue options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

COPD and Asthma Inhaler Reference Chart

For COPD and asthma management, use the following structured approach to inhaler selection based on disease severity and phenotype, prioritizing ICS-containing regimens for both conditions while avoiding SABA monotherapy in asthma.


ASTHMA INHALERS

Maintenance Therapy (Track 1 - Preferred)

  • Low-dose ICS-formoterol (combination inhaler)
    • Used for both maintenance AND as-needed relief
    • Replaces SABA-only approach 1
    • Superior for preventing severe and moderate-to-severe exacerbations 2

Maintenance Therapy (Track 2 - Alternative)

  • Regular low-dose ICS (separate inhaler)
    • Plus SABA as needed for rescue
    • Inferior to as-needed ICS/LABA for exacerbation prevention 2
    • Better lung function improvement than as-needed ICS/LABA 2

Step-Up Options for Uncontrolled Asthma

  • ICS/LABA as maintenance and reliever therapy (SMART)
    • Highest rank for preventing exacerbations 2
  • Higher-dose ICS for symptom control 2
  • Low-dose ICS/LABA for optimal lung function (FEV1) 2

Rescue/Reliever

  • SABA alone is NOT recommended as monotherapy 1
  • Use ICS-formoterol as needed (Track 1) OR SABA with separate ICS (Track 2)

COPD INHALERS

Initial Maintenance Therapy (Symptomatic Patients)

  • Long-acting bronchodilator monotherapy:
    • Tiotropium (LAMA, once daily) OR
    • Salmeterol/Formoterol (LABA, twice daily)
    • Superior to short-acting agents for lung function, dyspnea, exacerbations 3

Step-Up for Persistent Symptoms

  • LAMA/LABA dual therapy (combination)
    • Add second class of long-acting bronchodilator 4, 3

High Exacerbation Risk (≥2 exacerbations/year)

  • LAMA/LABA/ICS triple therapy (single inhaler preferred)
    • Reduces moderate-severe exacerbations by 24% vs LAMA/LABA 4
    • Use moderate-dose ICS (mortality benefit over low-dose) 4
    • Number needed to treat: 4 patients/year to prevent one exacerbation 4
    • Number needed to harm: 33 patients/year for one pneumonia 4

Blood Eosinophil Guidance for ICS Use

  • ≥300 cells/μL: Strong indication for ICS-containing therapy 4
  • <300 cells/μL: Consider avoiding ICS or stepping down carefully 4

Refractory Exacerbators (Despite Triple Therapy)

Add-on therapies in order of recommendation:

  1. Macrolide maintenance (if normal QT, no drug interactions, no mycobacterial infection) 4
  2. Roflumilast OR N-acetylcysteine (for chronic bronchitic phenotype) 4

Rescue/Reliever

  • Short-acting beta-agonist (SABA) with or without short-acting anticholinergic
    • MDI with spacer equivalent to nebulizer 5

ACUTE EXACERBATIONS

COPD Exacerbation Treatment

  • Bronchodilators: SABA ± short-acting anticholinergic 5
  • Systemic corticosteroids: Prednisone 40 mg daily × 5 days 5
  • Antibiotics: 5-7 days if indicated (purulent sputum) 5

Asthma Exacerbation

  • SABA for immediate relief
  • Systemic corticosteroids as needed
  • Consider eosinophil levels for steroid responsiveness 5

CRITICAL PITFALLS TO AVOID

  1. Never use SABA monotherapy in asthma - all patients need ICS-containing therapy 1
  2. Never use ICS monotherapy in COPD - always combine with long-acting bronchodilators 4
  3. Do not step down from triple therapy in high-risk COPD exacerbators - especially with eosinophils ≥300 4
  4. Avoid theophylline and oral corticosteroid maintenance in COPD 4
  5. High-dose ICS not necessary in COPD - flat dose-response curve, use moderate dose 4
  6. Verify inhaler technique before escalating therapy - poor technique mimics treatment failure 6

DEVICE SELECTION CONSIDERATIONS

Assess three key patient factors before prescribing:

  • Cognitive function - can they understand instructions?
  • Manual dexterity - can they coordinate actuation?
  • Inhalation ability - adequate inspiratory flow? 6

At follow-up, ask: "Does your current treatment help your breathing?"

  • If YES: Continue therapy, review technique
  • If NO: Assess technique and adherence before changing medication 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.